The phosphodiesterase 4 (PDE4) enzyme family plays a pivotal role in regulating levels of
the second messenger cAMP. Consequently, PDE4 inhibitors have been investigated as a …

Abstract Phosphodiesterase 5 (PDE5) is one of the most well-studied phosphodiesterases
(PDEs) that specifically targets cGMP typically generated by nitric oxide (NO)-mediated …

Intracellular levels of cyclic nucleotide second messengers are regulated predominantly by
the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Recent …

Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors
has reached a state of maturity. Standard issues in medicinal chemistry, such as potency …

After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors,
roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3, 5-di-chloropyrid-4-yl]-benzamide) …

The search for novel phosphodiesterase Type 4 (PDE4) inhibitors remains one of the most
active fields within the pharmaceutical industry. Recent progress within the clinical …

PDE4 inhibitors have been in development as a novel anti‐inflammatory therapy since the
1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary …

Phosphodiesterase-4 (PDE4) is the predominant enzyme in some specific cell types that is
responsible for the degradation of the second messenger, cAMP. Consequently, PDE4 plays …

Selective phosphodiesterase (PDE) 4 and dual PDE 3/4 inhibitors have attracted
considerable interest as potential therapeutic agents for the treatment of respiratory …

Phosphodiesterase-4 (PDE4) is an important cAMP-metabolising enzyme in immune and
inflammatory cells, airway smooth muscle and pulmonary nerves. The phosphodiesterase 4 …